Hualing Pharmaceutical announced on December 31, 2024, that its subsidiary Hualing Shanghai has officially issued a termination notice to Bayer, ending the commercial cooperation agreement between the two parties for Huatai Ning® (dorzagliatin tablets) in China starting January 1, 2025. This move aims to transition the commercialization responsibility of Huatai Ning® in China to Hualing Pharmaceutical itself. Huatai Ning® is a pioneering glucokinase activator developed by Hualing Pharmaceutical for the treatment of type 2 diabetes.Hualing Pharmaceutical stated that Bayer and the company have launched a friendly, patient-centered transition plan to ensure a smooth handover of commercialization responsibilities. This decision stems from the written notice of intent previously issued by Hualing Shanghai to Bayer on November 21, 2024. The company is committed to providing shareholders with timely updates on any significant developments regarding Huatai Ning® in accordance with listing rules and applicable laws.

Hualing Pharmaceutical announced on December 31, 2024, that its subsidiary Hualing Shanghai has officially issued a termination notice to Bayer, ending the commercial cooperation agreement between the two parties for Huatai Ning® (dorzagliatin tablets) in China starting January 1, 2025. This move aims to transition the commercialization responsibility of Huatai Ning® in China to Hualing Pharmaceutical itself. Huatai Ning® is a pioneering glucokinase activator developed by Hualing Pharmaceutical for the treatment of type 2 diabetes.Hualing Pharmaceutical stated that Bayer and the company have launched a friendly, patient-centered transition plan to ensure a smooth handover of commercialization responsibilities. This decision stems from the written notice of intent previously issued by Hualing Shanghai to Bayer on November 21, 2024. The company is committed to providing shareholders with timely updates on any significant developments regarding Huatai Ning® in accordance with listing rules and applicable laws.